15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 13 firms covering BioNTech SE, 10 rate it Buy or better, 3 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $94.00 to $158.00, a moderate spread. The average target of $128.00 sits 39% above the current $92.37. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.66 next quarter toward $-4.33 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS13 ratings
Moderate Buy
Strong Buy00%
Buy1077%
Hold323%
Sell00%
Strong Sell00%
Based on 13 analysts giving stock ratings to BioNTech SE.
As of Jul, 10 of 13 firms rate BNTX a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BNTX EPS & revenue forecast
EPS · NEXT QUARTER
$0.66
Range $-0.02 – $1.24 · 3 analysts · -647% YoY
Next period, 3 analysts expect BioNTech SE to earn $0.66 a share (range $-0.02 – $1.24), versus $-0.12 a year earlier. Full-year consensus is $-4.26, growing to $-4.33 the year after.
REVENUE · NEXT QUARTER
$1.2B
Range $886.0M – $1.5B · 3 analysts · -23% YoY
Revenue is expected to reach $1.2B (range $886.0M – $1.5B), -23.2% year-over-year. Full-year consensus is $2.2B, rising to $2.2B next year.
Top analysts covering BioNTech SE
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BNTX.
#1
Jessica Fye
JP Morgan · Rank #64
Hold
$120.00+29.9% to target
Overall win rate
52%
+ Follow
#2
RB
Robert Burns
HC Wainwright & Co. · Rank #195
Buy
$130.00+40.7% to target
Overall win rate
38%
+ Follow
#3
TA
Tazeen Ahmad
B of A Securities · Rank #275
Buy
$125.00+35.3% to target
Overall win rate
41%
+ Follow
#4
John Newman
Canaccord Genuity · Rank #340
Buy
$158.00+71.1% to target
Overall win rate
30%
+ Follow
#5
Terence Flynn
Morgan Stanley
Buy
$119.00+28.8% to target
Coverage
—
+ Follow
BNTX stock forecast FAQ
What is BNTX's average 12-month price target?+
The 13 analysts with a live target average $128.00 for BioNTech SE over the next 12 months, ranging from a $158.00 high to a $94.00 low.
Is BNTX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 13 analyst ratings, 10 are Buy or Strong Buy, 3 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for BNTX?+
The Street-high target is $158.00 (Canaccord Genuity), and the Street-low is $94.00 (TD Cowen). The average of all 13 active targets is $128.00.
How many Wall Street analysts cover BNTX?+
13 analysts have an active rating on BioNTech SE, and 13 firms carry a live 12-month price target.
Who is the most accurate analyst covering BNTX?+
Among analysts who currently cover BNTX, Jessica Fye of JP Morgan has the strongest overall Quantellect track record (Rank #64). Their current call is Hold with a $120.00 target.
What is BioNTech SE's projected EPS for next quarter?+
The consensus estimate is $0.66 per share (range $-0.02 – $1.24) across 3 analysts. Full-year EPS is projected at $-4.26, rising to $-4.33 the following year.
How much revenue is BioNTech SE expected to report next quarter?+
Consensus revenue is $1.2B (range $886.0M – $1.5B). Full-year revenue is projected at $2.2B, growing to $2.2B next year.
Have analysts been upgrading or downgrading BNTX lately?+
As of Jul, 10 of 13 firms rate BNTX a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BNTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
